A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: incorporated (115), integrated (151)

Colorectal multidisciplinary team - patient information

Description
Following your diagnosis of bowel (colorectal) cancer, you will be cared for by a team of medical experts and health professionals
Url
/Media/UHS-website-2019/Patientinformation/Cancercare/Colorectal-multidisciplinary-team-1152-PIL.pdf

Endometrial-Dostarlimab

Description
Chemotherapy Protocol GYNACOLOGICAL CANCER Dostarlimab Regimen  Endometrial - Dostarlimab Indication  Dostarlimab is indicated for patients with; - proven histological diagnosis of endometrial carcinoma
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Uterine-cancer/Dostarlimab.pdf

Carfilzomib-Dexamethasone(20) Ver1

Description
Chemotherapy Protocol MYELOMA Carfilzomib-Dexamethasone (20) Regimen • Myeloma – Carfilzomib-Dexamethasone (20) Indication • Carfilzomib in combination with dexamethasone is an option for
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/carfilzomib-dexamethasone20-ver1.pdf

Carfilzomib(14 day)-Dexamethasone(20) Ver1

Description
Chemotherapy Protocol MYELOMA Carfilzomib (14 day)-Dexamethasone (20) Regimen  Myeloma – Carfilzomib-Dexamethasone (20) Indication  Carfilzomib in combination with dexamethasone is an
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/carfilzomib14-day-dexamethasone20-ver1.pdf

Welcome to E1 Ocean ward - patient information

Description
This booklet has been written to help you and your family prepare for your child's stay with us on E1 Ocean
Url
/Media/UHS-website-2019/Patientinformation/Childhealth/Welcome-to-E1-Ocean-ward-1264-PIL.pdf

AMS FLIER summary 2022 - cohort 3 applications open

Description
Future Leaders in Innovation, Enterprise and Research (FLIER) Programme The Academy of Medical Sciences is pioneering a unique programme to develop
Url
/Media/Southampton-Clinical-Research/Grants/AMS-FLIER-summary-2022-cohort-3-applications-open.pdf

Durvalumab_14day

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (14 day) Regimen • NSCLC - Durvalumab (14 day) Indication • Stage 3 NSCLC after
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab-14day.pdf

Durvalumab(28day-1500mg)

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (28 day – 1500mg) Regimen • NSCLC - Durvalumab (28 day – 1500mg) Indication • Durvalumab is
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab28day-1500mg.pdf

MesoCisPemVer1.3

Description
Chemotherapy Protocol MESOTHELIOMA CISPLATIN-PEMETREXED Regimen Mesothelioma – Cisplatin-Pemetrexed Indication F
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Mesothelioma/MesoCisPemVer1.3.pdf

Nivolumab ver 1 (NSCLC)

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Nivolumab This regimen may require funding. Regimen NSCLC – Nivolumab Indication Metastatic squamous non
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Nivolumab-ver-1.pdf
321 to 330 of 1000
Previous … 31 32 33 34 35 … Next